Abstract: Joline De Groof (Amsterdam, Netherlands) presented data from the LIR!C trial, which was designed to determine the optimum treatment of recurrent ileocecal Crohn's disease that is refractory to thiopurine or steroid treatment. 143 patients were randomly assigned to receive either infliximab (n=70) or laparoscopic ileocecal resection (n=73). 65 patients started infliximab treatment, while 70 patients underwent ileocecal resection. After correcting for baseline differences in quality of life, the mean difference in Inflammatory Bowel Disease Questionnaire score at 1 year (the study's primary endpoint) was 5·8 points (95% CI −4·7 to 16·3; p=0·28) in favour of surgery. Assessment of costs suggested that costs were substantially lower for surgery than for infliximab.
Publication Year: 2016
Publication Date: 2016-12-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 6
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot